KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018

Market: Pharmaceuticals and Healthcare

Global, 32 pages report, published by GlobalData

Report ThumbnailSeptember-2018
KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018

Summary

This KOL Insight briefing focuses on KOLs views of Pipeline Therapy Data Presented at EULAR 2018.

Questions topics -
- Opinion on abatacept failing to achieve its primary endpoint in its Phase III LN trial
- Views on the Phase III safety data for abatacept in LN
- Expectations regarding abatacept’s future development in lupus
- Opinion on ustekinumab’s ability to achieve partial improvements using SL

Read More
  • Table of Contents
  • Executive Summary
  • Background
  • Research Panel Composition
  • Results & Implications
  • Appendix
Read More

Please select a license type

Share

Related Products

GlobalDataKOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018Product ThumbnailKOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018, Industry ReportProduct #: 1194219
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2019 Global Market Analyst. All Rights Reserved